Tranont Welcomes Dr. Erin Glynn, Metabolic Health and Nutrition Expert, to Its Scientific Advisory Board
Dr. Glynn brings decades of experience in metabolic health, nutrition and supplement innovation to support Tranont's mission to impact 1 billion lives
LEHI, Utah, April 30, 2025--(BUSINESS WIRE)--Tranont announces the newest member of its Scientific Advisory Board, Dr. Erin Glynn—a renowned expert in metabolic health, nutrition and product development with over 20 years of experience in academia and the dietary supplement industry.
In her role on the Scientific Advisory Board, Glynn will work closely with Tranont's leadership and product teams to guide innovation, oversee scientific product development and provide educational support to Tranont associates. With a passion for simplifying complex science, Glynn aims to empower Tranont's field leaders with tools and training that make sharing product benefits easier and more impactful.
Glynn's appointment emphasizes Tranont's focus on women's health and strengthens representation and expertise in this area. She will play a prominent, forward-facing role—shaping and communicating Tranont's mission to simplify women's health with effective, science-backed products that integrate seamlessly into daily life. Glynn will develop solutions that help women feel and perform at their best every day.
"I'm thrilled and honored to join the Tranont family as part of the Scientific Advisory Board," said Glynn. "What truly drew me to Tranont was the company's uniqueness, quality formulations and mission to impact 1 billion lives for good. From transformative products like DHS to women's health formulations such as Tranont For Her and the new Creatine formula, it's clear that Tranont is committed to creating solutions that improve people's lives."
Glynn holds a bachelor's degree in exercise physiology from Texas A&M University and a doctorate in preventive medicine and community health from the University of Texas Medical Branch. She furthered her expertise through a postdoctoral fellowship at Duke University's Stedman Nutrition & Metabolism Center, focusing on advanced metabolic research and clinical application. Throughout her career, Glynn has authored more than 30 peer-reviewed research publications and presented her work at leading scientific conferences nationwide.
After more than a decade in academic research, Glynn transitioned into the nutraceutical industry, where she has led research and development teams and developed clinically supported products for multi-million-dollar brands. Her approach blends science with a deep passion for wellness, product innovation and education.
"Dr. Glynn's expertise in metabolic and gut health will be instrumental in driving future product innovations, particularly in underserved areas like women's health," said Russell Losee, Co-Founder and COO at Tranont. "Her holistic approach aligns perfectly with Tranont's commitment to developing life-changing health products and providing associates with the resources they need to succeed."
To learn more about Tranont and its growing Scientific Advisory Board, visit www.tranont.com/about/scientific-advisory-board.
About Tranont
Tranont changes lives through achievable, science-driven solutions that simplify wellness. With clinically validated ingredients and research-backed formulations, our products are designed to make holistic health simple, effective, and seamlessly fit into your daily routine, so you can feel and perform at your best every day.
Tranont is a movement focused on improving women's health, building wealth, and providing service within communities, powered by science and made for real life. By joining Tranont as an associate, you can transform lives with our products while building personal wealth and reaching your financial and lifestyle goals. Tranont is on a mission to change lives and inspire meaningful, lasting transformations.
Discover more about improving your health, creating more wealth and leaving a lasting impact by visiting www.tranont.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250429511976/en/
Contacts
Mark FredricksonSnappConner PR801-806-0161mark@snappconner.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
CORRECTING and REPLACING Majority of Ontarians Want Provincial Government to Prioritize Spending on Public Hospitals Than Private Clinics: New Poll
TORONTO--(BUSINESS WIRE)--The media conference time should be 10:00 am instead of 9:30 am. The updated release reads: MAJORITY OF ONTARIANS WANT PROVINCIAL GOVERNMENT TO PRIORITIZE SPENDING ON PUBLIC HOSPITALS THAN PRIVATE CLINICS: NEW POLL OCHU-CUPE media conference at 10:00 am on Monday to release full findings of new Nanos poll on privatization Just over 10 days after the recent Ontario budget allocated $280 million for expansion of surgeries and diagnostic tests in private clinics while restraining hospital funding, a new poll shows that 73 per cent of Ontarians want the government to prioritize investments in public health care. The Nanos poll conducted in May surveyed over a thousand Ontarians about privatization of hospital services and their perception about staffing in public hospitals. The poll was commissioned by CUPE's Ontario Council of Hospital Unions (OCHU-CUPE), which will be releasing a supplementary report on privatization at a media conference at Queen's Park on Monday morning. :gv/cope491
Yahoo
3 hours ago
- Yahoo
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass., June 06, 2025--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn. View source version on Contacts Media Contact: Marissa Klaassenmedia@ Investor Relations Contact: Joshua Youngir@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
3 hours ago
- Business Wire
Quanterix to Present at Goldman Sachs Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46 th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9 th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast presentation can be accessed from the Investors section of the company's website at A replay of the webcast will be available for a limited period following the conference. To learn more about Quanterix, visit To learn more about Quanterix's Simoa ® technology, visit About Quanterix From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa ® technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,400 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn.
